Is kratom being banned in 2026? There is no nationwide federal ban on traditional kratom leaf as of November 3, 2026. However, the Drug Enforcement Administration (DEA) has proposed stricter federal controls on concentrated 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MGPI), two opioid-active compounds associated with certain products marketed as kratom.

In October 2026, the DEA withdrew its earlier scheduling proposal and introduced updated restrictions intended to distinguish concentrated or chemically enhanced products from traditional botanical kratom. Under the revised notice, November 13, 2026, is the earliest possible date for the DEA to publish the new temporary scheduling order, not a confirmed ban date.

For patients who use concentrated 7-OH to manage pain, cravings, or withdrawal symptoms, these developments may raise concerns about product availability and dependence. Understanding the proposed changes and available treatment options can help you make informed decisions about your health.

If you’re concerned about dependence or withdrawal, DevotedDOc offers kratom addiction treatment evaluations to help determine appropriate care options.

Medical content reviewed by Dr. Matthew Berrios, DO, CEO of DevotedDOc. This article is for educational purposes and does not replace individualized medical or legal advice. Kratom and concentrated 7-OH products are not FDA-approved treatments for opioid use disorder.

Is There a Kratom Ban in 2026?

As of November 3, 2026, traditional, unenhanced kratom leaf is not subject to a nationwide federal Schedule I ban. However, certain kratom-related compounds are already federally controlled, and the DEA has proposed additional restrictions targeting concentrated 7-OH and MGPI.

According to the DEA’s October 14, 2026, Federal Register notice, the agency intends to temporarily place 7-OH and MGPI into Schedule I when they exceed specified concentration or chemical-ratio thresholds.

This is an important distinction because a notice of intent does not immediately establish new federal controls. The DEA must publish a temporary scheduling order before those restrictions take effect.

State laws may already prohibit or restrict certain kratom-related products, even while the updated federal proposal remains pending.

When Could the Federal 7-OH Ban Take Effect?

The earliest possible date for the DEA’s updated temporary scheduling order is November 13, 2026.

The October notice states that the order may be published on or after that date. However, November 13 is not a guaranteed effective date, and the DEA could issue the order later.

Until the new order is published, the revised scheduling proposal remains pending. Existing federal controls on other kratom-related compounds and applicable state laws continue to matter.

For patients who regularly use concentrated 7-OH, the proposed changes are a reason to discuss dependence or withdrawal concerns with a healthcare provider rather than waiting for product availability to change.

What Changed in the DEA’s October 2026 7-OH Update?

The DEA previously announced its intent to temporarily schedule certain 7-OH products in July 2026. However, that proposal did not result in a temporary scheduling order.

On October 8, 2026, the Department of Health and Human Services (HHS) provided updated recommendations for regulating concentrated 7-OH and MGPI. The DEA subsequently withdrew its earlier 7-OH notice and published a revised proposal on October 14.

The updated approach focuses on product concentration and chemical composition, rather than applying the same scheduling criteria to all products containing trace amounts of these compounds.

In its October 2026 announcement, HHS explained that the revised framework was intended to target concentrated or chemically altered products while distinguishing them from traditional botanical kratom.

What Are the Proposed Federal 7-OH Thresholds?

Under the October 2026 proposal, Schedule I controls would apply when 7-OH or MGPI, individually or combined, exceeds:

• 1 milligram per gram in solid products, including powders, tablets, and capsules.
• 1 milligram per milliliter in liquid products.

The proposal also includes a separate chemical-ratio rule. A product may meet the proposed scheduling criteria when the amount of mitragynine divided by the amount of 7-OH, MGPI, or their combined amount is less than 100.

This means a product could meet the proposed criteria through either its concentration or its chemical composition.

These thresholds are legal classification criteria, not recommended consumption amounts or established safe limits.

The DEA specifically states that neither the agency nor HHS has determined that products below the proposed thresholds are safe.

Are Other Kratom-Related Compounds Already Controlled?

Yes. In August 2026, the DEA temporarily placed three related substances into Schedule I: mitragynine pseudoindoxyl (MGPI), MGM-15, and MGM-16.

The October proposal would revise the scheduling approach for MGPI by applying the new thresholds if the updated order takes effect.

The existing temporary controls remain in place unless they expire or are superseded by a new order.

For consumers, this means a product’s legal status may depend on its specific ingredients and chemical composition, not simply whether its packaging says kratom.

Traditional Kratom vs. Concentrated 7-OH: Why the Difference Matters

One of the most important distinctions in the 2026 kratom ban discussion is that traditional kratom leaf and concentrated 7-OH products are not interchangeable.

Kratom comes from the Mitragyna speciosa tree, which grows naturally in Southeast Asia. Its leaves contain several alkaloids, primarily mitragynine, along with much smaller amounts of 7-hydroxymitragynine.

Concentrated 7-OH products contain substantially higher levels of this opioid-active compound than traditional botanical preparations. Some are produced through chemical conversion processes and sold as tablets, gummies, liquids, or other enhanced formulations.

Understanding what is 7-OH can help explain its opioid-related effects. For a closer comparison of their ingredients and potential risks, our guide to kratom vs. 7-OH explores these differences.

What Recent Medical Research Says About Concentrated 7-OH

An October 2026 peer-reviewed article by John Stogner, PhD, published in the Journal of the American Board of Family Medicine, examines the growing availability of concentrated 7-OH products and the challenges they create for healthcare providers and policymakers.

The article, Hydroxymitragynine Kratom Products Creates Challenges for Health Care and Policy, discusses how concentrated and semisynthetic 7-OH products differ from traditional botanical kratom.

It identifies concerns involving opioid-like effects, respiratory depression, dependence, withdrawal, and products with uncertain composition.

The author also raises an important question: Could restrictions on concentrated 7-OH products unintentionally lead some dependent individuals to seek other unregulated substances or more dangerous opioids?

This is a potential public health concern, not an established outcome. It also does not mean concentrated 7-OH is a safe or effective alternative to approved addiction treatment.

Is Kratom Legal? Understanding Federal and State Kratom Laws

The answer to is kratom legal depends on the product, its ingredients, and the jurisdiction where it is sold or possessed.

At the federal level, traditional kratom leaf has not been placed under a nationwide Schedule I ban. However, certain related compounds are already controlled, and the DEA has proposed additional restrictions involving concentrated 7-OH and MGPI.

Federal scheduling is also different from FDA approval. A substance may fall outside a particular DEA scheduling order without being approved as a medication or considered safe for consumption.

The Congressional Research Service’s analysis of kratom regulation provides additional background on federal legal issues involving kratom and related substances.

Why Kratom Laws Differ Between States

Some states prohibit kratom or particular kratom-derived compounds, while others regulate product labeling, testing, age restrictions, and sales.

Certain states have adopted versions of the Kratom Consumer Protection Act, which establishes requirements intended to improve product transparency and consumer protection.

These requirements are discussed in our article about kratom consumer protection laws. State-specific regulations can also be seen in discussions of kratom laws in Florida.

Because state regulations may change independently of federal scheduling, consumers should verify current requirements in their jurisdiction rather than assuming that a product sold online or in a retail store is legal.

What Does the 2026 Kratom Ban Mean for Patients?

For patients who regularly use concentrated 7-OH, the proposed restrictions may affect more than where a product can be purchased.

Some individuals report using kratom or 7-OH to manage pain, reduce opioid cravings, or cope with withdrawal symptoms. However, neither traditional kratom nor concentrated 7-OH is an FDA-approved treatment for opioid use disorder.

If someone has developed physical dependence, a sudden interruption in use may lead to withdrawal symptoms and increased cravings.

This is why discussions about potential product restrictions should also include access to medical evaluation and appropriate treatment.

What Happens If You Depend on 7-OH?

Regular exposure to concentrated 7-OH can lead to physical dependence, meaning the body adapts to repeated use.

When someone who has developed dependence reduces or stops using the substance, withdrawal symptoms may occur. These can include anxiety, restlessness, sweating, muscle aches, gastrointestinal discomfort, difficulty sleeping, and cravings.

The severity and duration of withdrawal can vary depending on the product, frequency of use, other substances involved, and individual health factors.

Patients experiencing these symptoms can learn more about kratom and 7-OH withdrawal and discuss appropriate care with a healthcare provider.

If you use concentrated 7-OH regularly, consider seeking medical guidance before making abrupt changes. Avoid attempting to manage withdrawal by switching to illicit opioids, using someone else’s prescription medication, or combining sedating substances.

Why Product Labeling Is Another Concern

Some products marketed as kratom may contain concentrated 7-OH or other opioid-active compounds without clearly communicating their strength.

A person purchasing a product labeled as a botanical extract may not realize that its chemical composition differs significantly from traditional kratom leaf.

The FDA warns about serious risks associated with products containing 7-OH, including addiction, withdrawal, and other adverse effects.

Consumers should not assume that a product is safe because it is marketed as natural, sold over the counter, or falls below a proposed federal scheduling threshold.

What Are the Health Risks of Concentrated 7-Hydroxymitragynine?

Concentrated 7-OH acts on opioid receptors and can produce effects associated with other opioids, including sedation, physical dependence, and potentially dangerous respiratory depression.

These risks may increase when concentrated 7-OH is combined with alcohol, benzodiazepines, prescription opioids, or other substances that affect breathing and alertness.

Although human research remains limited, preclinical findings and reports of serious adverse events have raised concerns among healthcare professionals.

Can Concentrated 7-OH Cause an Overdose?

Yes. Concentrated 7-OH can cause serious opioid-related toxicity, including respiratory depression.

Warning signs of a possible opioid overdose include very slow or absent breathing, inability to wake the person, unusual snoring or gurgling sounds while unresponsive, and blue or gray discoloration around the lips or fingernails.

If an overdose is suspected, call 911 immediately. Administer naloxone if available, follow emergency dispatcher instructions, and stay with the person until medical help arrives.

Naloxone may reverse opioid-related respiratory depression, although clinical evidence specific to concentrated 7-OH overdose remains limited. Emergency medical evaluation is still necessary.

The CDC’s guidance on naloxone explains how this medication works during a suspected opioid overdose.

Can Suboxone Help Patients With Kratom or 7-OH Dependence?

For patients struggling with opioid-related dependence, professional treatment may help address withdrawal symptoms, cravings, and ongoing substance use.

Buprenorphine, one of the active ingredients in Suboxone, is an established medication for opioid use disorder. Healthcare providers have also reported using buprenorphine-based treatment in selected cases involving kratom or concentrated 7-OH dependence.

However, research specifically evaluating buprenorphine for kratom or 7-OH dependence remains limited. Treatment decisions require individualized clinical assessment.

Why Medical Evaluation Matters Before Starting Suboxone

A healthcare provider needs to understand which substances a patient has been using, how frequently they are used, whether withdrawal symptoms are present, and what other medications may be involved.

Starting buprenorphine at an inappropriate time after certain opioid exposures can cause precipitated withdrawal, a sudden worsening of withdrawal symptoms.

For this reason, patients should not attempt to determine their own medication schedule based on general online instructions.

Our article on Suboxone treatment after 7-OH use discusses relevant treatment considerations, including why clinical supervision matters.

For eligible patients, DevotedDOc provides online Suboxone treatment and ongoing physician-led care when clinically appropriate.

What Should Patients Do Before the Proposed 7-OH Restrictions Take Effect?

As of November 3, 2026, the updated federal scheduling proposal remains pending, with November 13 representing the earliest possible date for the DEA to publish the temporary order.

Patients who regularly use concentrated 7-OH do not need to wait for a regulatory change to discuss their health concerns.

If you experience withdrawal symptoms when you stop using a product, need increasing amounts to achieve the same effects, or struggle to control your use, these may be signs of physical dependence or a substance use disorder.

A healthcare provider can review your substance use history, assess withdrawal symptoms, evaluate possible medication interactions, and discuss appropriate treatment options.

It can also be helpful to explain exactly which products you have been using and provide product packaging or photographs when possible.

The goal is not simply to respond to a possible ban. It is to address dependence, reduce overdose risks, and establish an appropriate plan for ongoing care.

Frequently Asked Questions About the Kratom Ban in 2026

Is kratom banned in the United States in 2026?

As of November 3, 2026, there is no nationwide federal Schedule I ban on traditional kratom leaf. However, certain related compounds are already controlled, and the DEA has proposed additional restrictions targeting concentrated 7-OH and MGPI.

When does the 7-OH ban take effect?

November 13, 2026, is the earliest possible date for the DEA’s revised temporary scheduling order. The actual effective date depends on when the agency publishes the order.

Is 7-OH illegal right now?

As of November 3, 2026, the revised federal scheduling proposal for 7-OH had not taken effect. However, particular products may already be restricted or prohibited under state laws or other applicable federal requirements.

Is traditional kratom the same as 7-OH?

No. Traditional kratom leaf contains naturally occurring alkaloids, including small amounts of 7-OH. Concentrated 7-OH products may contain substantially higher levels of this opioid-active compound and carry different risks.

Are products below the DEA’s proposed thresholds safe?

Not necessarily. The DEA specifically states that products falling below the proposed scheduling thresholds have not been determined to be safe. Legal classification and medical safety are separate questions.

Can stopping 7-OH cause withdrawal?

Yes. Regular concentrated 7-OH use can lead to physical dependence, and reducing or stopping use may cause opioid-like withdrawal symptoms. A healthcare provider can evaluate symptoms and discuss appropriate treatment options.

Can Suboxone help with 7-OH withdrawal?

Buprenorphine-based treatment has been reported in selected clinical cases involving kratom and 7-OH dependence. However, evidence remains limited, and treatment should be determined through individualized medical evaluation.

Get Support for Kratom or 7-OH Dependence With DevotedDOc

The 2026 kratom ban discussion continues to evolve, but patients should understand one important distinction: traditional kratom and concentrated 7-OH products are not the same, and their health risks and legal status may differ.

While the DEA’s updated scheduling proposal remains pending, people who regularly use concentrated 7-OH may already face challenges involving dependence, cravings, or withdrawal.

DevotedDOc provides physician-led online opioid addiction treatment, including clinical evaluations, medication management when appropriate, and ongoing recovery support.

If you’re concerned about concentrated 7-OH use, a healthcare provider can assess your symptoms, review your substance use history, and help determine appropriate care options.

Concerned about dependence or withdrawal? Schedule an online appointment with DevotedDOc to discuss your treatment options and recovery goals.